197 related articles for article (PubMed ID: 37188812)
1. Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies.
Zhang F; Jenkins J; de Carvalho RVH; Nakandakari-Higa S; Chen T; Abernathy ME; Baharani VA; Nyakatura EK; Andrew D; Lebedeva IV; Lorenz IC; Hoffmann HH; Rice CM; Victora GD; Barnes CO; Hatziioannou T; Bieniasz PD
Nat Microbiol; 2023 Jun; 8(6):1051-1063. PubMed ID: 37188812
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.
Jensen JL; Sankhala RS; Dussupt V; Bai H; Hajduczki A; Lal KG; Chang WC; Martinez EJ; Peterson CE; Golub ES; Rees PA; Mendez-Rivera L; Zemil M; Kavusak E; Mayer SV; Wieczorek L; Kannan S; Doranz BJ; Davidson E; Yang ES; Zhang Y; Chen M; Choe M; Wang L; Gromowski GD; Koup RA; Michael NL; Polonis VR; Rolland M; Modjarrad K; Krebs SJ; Joyce MG
J Virol; 2023 Jul; 97(7):e0159622. PubMed ID: 37395646
[TBL] [Abstract][Full Text] [Related]
3. Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants.
Sun CP; Chiu CW; Wu PY; Tsung SI; Lee IJ; Hu CW; Hsu MF; Kuo TJ; Lan YH; Chen LY; Ng HY; Chung MJ; Liao HN; Tseng SC; Lo CH; Chen YJ; Liao CC; Chang CS; Liang JJ; Draczkowski P; Puri S; Chang YC; Huang JS; Chen CC; Kau JH; Chen YH; Liu WC; Wu HC; Danny Hsu ST; Wang IH; Tao MH
Mol Ther; 2023 Nov; 31(11):3322-3336. PubMed ID: 37689971
[TBL] [Abstract][Full Text] [Related]
4. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
[TBL] [Abstract][Full Text] [Related]
5. Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses.
Li M; Ren Y; Aw ZQ; Chen B; Yang Z; Lei Y; Cheng L; Liang Q; Hong J; Yang Y; Chen J; Wong YH; Wei J; Shan S; Zhang S; Ge J; Wang R; Dong JZ; Chen Y; Shi X; Zhang Q; Zhang Z; Chu JJH; Wang X; Zhang L
Nat Commun; 2022 Dec; 13(1):7957. PubMed ID: 36575191
[TBL] [Abstract][Full Text] [Related]
6. Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor.
Chia WN; Tan CW; Tan AWK; Young B; Starr TN; Lopez E; Fibriansah G; Barr J; Cheng S; Yeoh AY; Yap WC; Lim BL; Ng TS; Sia WR; Zhu F; Chen S; Zhang J; Kwek MSS; Greaney AJ; Chen M; Au GG; Paradkar PN; Peiris M; Chung AW; Bloom JD; Lye D; Lok S; Wang LF
Sci Adv; 2023 Jul; 9(30):eade3470. PubMed ID: 37494438
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.
Winkler ES; Chen RE; Alam F; Yildiz S; Case JB; Uccellini MB; Holtzman MJ; Garcia-Sastre A; Schotsaert M; Diamond MS
J Virol; 2022 Jan; 96(1):e0151121. PubMed ID: 34668780
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 strains bearing Omicron BA.1 spike replicate in C57BL/6 mice.
Ogger PP; MartÃn MG; Jang S; Zhou J; Brown J; Sukhova K; Furnon W; Patel AH; Cowton V; Palmarini M; Barclay WS; Johansson C
Front Immunol; 2024; 15():1383612. PubMed ID: 38742107
[TBL] [Abstract][Full Text] [Related]
9. Interaction Analysis of the Spike Protein of Delta and Omicron Variants of SARS-CoV-2 with hACE2 and Eight Monoclonal Antibodies Using the Fragment Molecular Orbital Method.
Hwang S; Baek SH; Park D
J Chem Inf Model; 2022 Apr; 62(7):1771-1782. PubMed ID: 35312321
[TBL] [Abstract][Full Text] [Related]
10. A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope.
VanBlargan LA; Adams LJ; Liu Z; Chen RE; Gilchuk P; Raju S; Smith BK; Zhao H; Case JB; Winkler ES; Whitener BM; Droit L; Aziati ID; Bricker TL; Joshi A; Shi PY; Creanga A; Pegu A; Handley SA; Wang D; Boon ACM; Crowe JE; Whelan SPJ; Fremont DH; Diamond MS
Immunity; 2021 Oct; 54(10):2399-2416.e6. PubMed ID: 34481543
[TBL] [Abstract][Full Text] [Related]
11. Hot spot profiles of SARS-CoV-2 and human ACE2 receptor protein protein interaction obtained by density functional tight binding fragment molecular orbital method.
Lim H; Baek A; Kim J; Kim MS; Liu J; Nam KY; Yoon J; No KT
Sci Rep; 2020 Oct; 10(1):16862. PubMed ID: 33033344
[TBL] [Abstract][Full Text] [Related]
12. Broadly neutralizing antibodies derived from the earliest COVID-19 convalescents protect mice from SARS-CoV-2 variants challenge.
Liu Q; Zhao H; Li Z; Zhang Z; Huang R; Gu M; Zhuang K; Xiong Q; Chen X; Yu W; Qian S; Zhang Y; Tan X; Zhang M; Yu F; Guo M; Huang Z; Wang X; Xiang W; Wu B; Mei F; Cai K; Zhou L; Zhou L; Wu Y; Yan H; Cao S; Lan K; Chen Y
Signal Transduct Target Ther; 2023 Sep; 8(1):347. PubMed ID: 37704615
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes.
Fan C; Cohen AA; Park M; Hung AF; Keeffe JR; Gnanapragasam PNP; Lee YE; Gao H; Kakutani LM; Wu Z; Kleanthous H; Malecek KE; Williams JC; Bjorkman PJ
Immunity; 2022 Dec; 55(12):2419-2435.e10. PubMed ID: 36370711
[TBL] [Abstract][Full Text] [Related]
14. S309-CAR-NK cells bind the Omicron variants
Ma MT; Jiang Q; Chen C-H; Badeti S; Wang X; Zeng C; Evans D; Bodnar B; Marras SAE; Tyagi S; Bharaj P; Yehia G; Romanienko P; Hu W; Liu S-L; Shi L; Liu D
J Virol; 2024 Jun; 98(6):e0003824. PubMed ID: 38767356
[TBL] [Abstract][Full Text] [Related]
15. Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses.
Wang Y; Liu M; Shen Y; Ma Y; Li X; Zhang Y; Liu M; Yang XL; Chen J; Yan R; Luan D; Wang Y; Chen Y; Wang Q; Lin H; Li Y; Wu K; Zhu T; Zhao J; Lu H; Wen Y; Jiang S; Wu F; Zhou Q; Shi ZL; Huang J
Cell Discov; 2022 Apr; 8(1):36. PubMed ID: 35443747
[TBL] [Abstract][Full Text] [Related]
16. Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening.
Yang X; Duan H; Liu X; Zhang X; Pan S; Zhang F; Gao P; Liu B; Yang J; Chi X; Yang W
J Virol; 2023 Jul; 97(7):e0061023. PubMed ID: 37367229
[TBL] [Abstract][Full Text] [Related]
17. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses.
Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM
PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993
[TBL] [Abstract][Full Text] [Related]
18. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
19. Distinct in vitro and in vivo neutralization profiles of monoclonal antibodies elicited by the receptor binding domain of the ancestral SARS-CoV-2.
Kwon HJ; Zhang J; Kosikova M; Tang W; Ortega-Rodriguez U; Peng H; Meseda CA; Pedro CL; Schmeisser F; Lu J; Kang I; Zhou B; Davis CT; Wentworth DE; Chen WH; Shriver MC; Barnes RS; Pasetti MF; Weir JP; Chen B; Xie H
J Med Virol; 2023 Mar; 95(3):e28673. PubMed ID: 36916782
[TBL] [Abstract][Full Text] [Related]
20. A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant.
Hingankar N; Deshpande S; Das P; Rizvi ZA; Wibmer CK; Mashilo P; Ansari MY; Burns A; Barman S; Zhao F; Mukherjee S; Torres JL; Chattopadhyay S; Mehdi F; Sutar J; Rathore DK; Pargai K; Singh J; Sonar S; Jakhar K; Dandotiya J; Bhattacharyya S; Mani S; Samal S; Singh S; Kshetrapal P; Thiruvengadam R; Batra G; Medigeshi G; Ward AB; Bhatnagar S; Awasthi A; Sok D; Bhattacharya J
PLoS Pathog; 2022 Apr; 18(4):e1010465. PubMed ID: 35482816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
